rct
    2013
    High Quality

    Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial

    Unknown authors

    Published in JAMA

    Key Findings

    Adding lutein/zeaxanthin or omega-3 fatty acids to the AREDS formulation did not further reduce progression to advanced AMD overall.

    Conclusions

    Key null result: omega-3 added no benefit; lutein/zeaxanthin is a safer beta-carotene substitute.

    Supplements Studied

    Omega-3 fatty acid supplementation did not reduce progression to advanced age-related macular degeneration.

    Zeaxanthin
    Compound

    Adding lutein and zeaxanthin to the AREDS formulation did not further reduce progression to advanced AMD overall.

    Lutein
    Compound

    Lutein plus zeaxanthin was a suitable substitute for beta-carotene in the AREDS formulation without added overall benefit for progression.

    Related Health Concerns

    Vision Changes
    Macular Degeneration

    Study Details

    Year:2013
    Quality Score:9/10

    Access Study

    View on DOIView on PubMedOriginal Source

    This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.